Moleculin Biotech
MBRX
4 hedge funds and large institutions have $1.42M invested in Moleculin Biotech in 2017 Q4 according to their latest regulatory filings, with funds opening new positions, 2 increasing their positions, reducing their positions, and 0 closing their positions.
477% more capital inflows, than outflows
Capital inflows: $173K | Capital outflows: $30K
0.39% more ownership
Funds ownership: 3.23% → 3.62% (+0.39%)
0% more funds holding
Funds holding: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$86.5K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$86.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Credit Suisse
Zurich,
Switzerland
|
-$29K |
| 2 |
Next Financial Group
Houston,
Texas
|
-$1K |
MBRX Hedge Fund Activity: Q4 2017 in Review
4 of the 4,420 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q4 2017, worth a combined $1.42M — down 9% from $1.56M a quarter earlier.
Fund positioning in MBRX was balanced in Q4 2017: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 0 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $86.5K. The largest seller was Credit Suisse, cutting an estimated $29K.
- 4 institutional investors held Moleculin Biotech (MBRX) as of Q4 2017, unchanged from Q3 2017.
- Funds reported $1.42M of Moleculin Biotech stock for Q4 2017, down 9% quarter-over-quarter.
- 0 funds opened new Moleculin Biotech positions in Q4 2017 and 0 closed out.
- The largest Moleculin Biotech buyer in Q4 2017 was Geode Capital Management, an estimated $86.5K added.
- The largest Moleculin Biotech seller in Q4 2017 was Credit Suisse, an estimated $29K sold.
Based on aggregated 13F filings for Q4 2017.